First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Teva Pharmaceutical Industries Ltd. (TEVA): the developments shaping its investment case

    Follow the evidence affecting Teva Pharmaceutical Industries Ltd.'s financing assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Teva Pharmaceutical Industries Ltd. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-19 · 3 reports
    Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
    Channel: Direct positive impact on UZEDY sales and market share due to demonstrated superior real-world outcomes, potentially leading to increased prescriptions and payer preference.
    Bullish· 1-3m
    2026-09-19 · 2 reports
    Teva real-world data demonstrates UZEDY reduces emergency care and medical costs
    Channel: Increased market penetration and physician preference for UZEDY due to demonstrated cost-effectiveness and improved patient outcomes, potentially leading to higher sales volume and market share.
    Bullish· 3-12m
    2026-09-19
    Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
    Channel: Direct product sales and market share gains due to demonstrated superior efficacy and cost-effectiveness, potentially leading to increased prescriptions and formulary inclusions.
    Bullish· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-09-11waccBullishHigher cost-of-debt tranche lifts blended WACC.
    2026-09-11interest_expenseBullishHigh-yield coupon materially raises interest burden.
    2026-09-11net_debtBullishSub-IG debt raise increases leverage and net debt.

    Event impact log

    12 events mapped to TEVA since 2026-08-26. Evidence through 2026-09-19.

    DateEventChannelDirectionHorizonImpact
    2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment ContinuityDirect positive impact on UZEDY sales and market share due to demonstrated superior real-world outcomes, potentially leading to increased prescriptions and payer preference.Bullish1-3m0.80
    2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantageImproved real-world data for UZEDY could enhance physician prescribing confidence and patient adherence, potentially leading to increased market share and sales volume for the drug. Reduced healthcare costs and ED visits may also appeal to payers, supporting favorable formulary placement.Bullish1-3m0.70
    2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsIncreased market penetration and physician preference for UZEDY due to demonstrated cost-effectiveness and improved patient outcomes, potentially leading to higher sales volume and market share.Bullish3-12m0.70
    2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia ContinuityDirect product competitive advantage and market share gain potential.Bullish1-3m0.80
    2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost ReductionsDirect product sales and market share gains due to demonstrated superior efficacy and cost-effectiveness, potentially leading to increased prescriptions and formulary inclusions.Bullish3-12m0.80
    2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare UtilizationImproved market positioning and formulary access for key product UZEDY, potentially leading to increased sales volume and better pricing power.Bullish1-3m0.80
    2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting InjectablesDirect product sales increase due to enhanced market perception and physician preference, potentially leading to increased market share.Bullish1-3m0.80
    2026-09-16NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor AmendmentPotential future competition in the generic ketamine market, if NRXP's product is approved.watch3-12m0.20
    2026-09-07Teva launches EUR and USD senior notes to refinance high-coupon 2028-2029 debtDirect reduction in interest expense due to refinancing higher-coupon debt with potentially lower-coupon new debt.Bullish1-3m0.70
    2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 DebtDirect financial optimization through debt refinancing.Bullish1-3m0.70
    2026-09-07Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 DebtDirect reduction in interest expense and improved debt maturity profile.Bullish1-3m0.80
    2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 FirmsPotential for increased competition in neurological disorder treatments, or opportunities for late-stage development/commercialization partnerships.watch3-12m0.40

    Continue this research

    Build your Teva Pharmaceutical Industries Ltd. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the TEVA entity page →

    Research Teva Pharmaceutical Industries Ltd. · $399/mo